Introduction
============

Although asthma and chronic obstructive pulmonary disease (COPD) are both defined by the presence of airflow obstruction; airway remodeling; and airway inflammation, the two conditions are clinically and pathophysiologically distinct.[@b1-copd-5-287]--[@b3-copd-5-287] Studies on the underlying inflammation demonstrate a difference in the preponderance of inflammatory cells and mediators in each disease. However, in clinical practice, it has been recognized that a firm diagnosis between these diseases is often difficult to achieve.[@b3-copd-5-287]--[@b7-copd-5-287] Therefore, it is quite common to observe patients with asthma showing COPD-like phenotypes, and vice versa, making it a priority to search for optimal prevention, treatment, and management strategies for these cases of coexisting lung obstructive diseases.

Asthma most often presents at a younger age as recurrent episodes of increased airway obstruction that may have varying frequency and intensity, which then become recognized as a chronic pattern of reversible airway obstruction.[@b1-copd-5-287] In a subset of patients with long-term disease, reversibility of airway obstruction is diminished (due to airway remodeling), and a disease pattern similar to COPD may ensue.[@b4-copd-5-287] Furthermore, smoking affects asthma by influencing the underlying airway inflammatory process;[@b8-copd-5-287] it increases airway hyperresponsiveness (AHR), by the induction of airway inflammation and geometric changes of the airways due to airway smooth muscle hypertrophy, mucus hypersecretion, and loss of alveolar attachments.[@b9-copd-5-287],[@b10-copd-5-287] Furthermore, increases in neutrophils have been described, thus resulting in asthmatics with a COPD phenotype.

COPD is a progressive disease of declining lung function, observed mainly in older adults with a history of cigarette smoking.[@b2-copd-5-287] However, although it is known that COPD is an inflammatory response of the lungs, characterized by chronic airflow limitation that is not fully reversible,[@b2-copd-5-287] there is a subgroup of COPD patients with reversibility, which has been associated with increased exhaled nitric oxide and sputum eosinophilia.[@b11-copd-5-287] COPD is often accompanied by AHR and smoking seems to be a risk factor for increasing AHR over time, whereas smoking cessation improves AHR, both in asthma and COPD patients.[@b12-copd-5-287]

Based on the above data, the aim of this study was: 1) to look for inflammatory parameters that might distinguish between asthma and COPD patients; and 2) to evaluate the inflammatory patterns in relation to airway reversibility and hyperreactivity in the subgroups of asthma and COPD that might lead to overlapping phenotypes; namely smoking asthmatics, and COPD patients with reversibility.

Methods
=======

A total of 110 patients (17 healthy subjects; 16 "healthy" smokers; 46 asthma patients: 24 smokers and 22 non-smokers; and 31 COPD patients: 10 COPD patients with reversibility and 21 without) participated in the study. COPD patients were all current smokers (\>15 pack-years) and so were smoker asthmatics (number of pack-years = packs smoked per day x years as a smoker). All "healthy" smokers were lifelong smokers (≥15 pack-years), with no history of lung disease, no chronic respiratory symptoms, and normal spirometry. Healthy non-smokers were asymptomatic and had no history of asthma or other respiratory disease, or any allergic condition. Atopic status was assessed by skin-prick testing using 13 common allergens applied to the forearm. The allergens tested (HAL Allergen Lab B.V., Haarlem, Netherlands) were house dust mites (*Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*), household pets (cat and dog), pollens (mixed grass, olive, mixed weed, and *Parietaria judaica*), and moulds (*Alternaria* and *Aspergillus fumigatus*). Histamine and glycerinated saline solution were used as positive and negative controls. A skin-prick test result was considered positive if the mean wheal diameter was ≥3 mm.

Asthma was diagnosed using the American Thoracic Society guidelines.[@b1-copd-5-287] Stable asthma was defined as no asthma exacerbation within the three months prior to study entry, and no respiratory infection or antibiotic use within the preceding six weeks. No smoking asthmatic met Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for Stage I disease (forced expiratory volume in one second (FEV~1~) \>80% predicted; FEV~1~/forced vital capacity (FVC) ratio \<70%).

COPD patients satisfied the European Respiratory Society (ERS) criteria[@b11-copd-5-287] for COPD and were selected according to the GOLD[@b13-copd-5-287] criteria for COPD stages I and II (FEV~1~/FVC ≤ 0.7, and FEV~1~ ≥ 0.8 and 0.5 \< FEV~1~ \< 0.8, respectively) and with no evidence of emphysema, based on high-resolution computed tomographic scans of the lungs and the diffusing capacity of lung for carbon monoxide (DLCO). COPD patients having reversibility \>9% of the predicted FEV~1~ were considered as COPD with reversibility.[@b14-copd-5-287],[@b15-copd-5-287]

All participants met the following criteria: no use of inhaled or oral corticosteroids in the previous three months, and no respiratory tract infection six weeks prior to the study. Patients with co-morbidities, such as bronchiectases, interstitial diseases, and heart failure, were excluded.

None of the healthy smokers or non-smokers were receiving either long-acting bronchodilators or leukotriene modifiers. Asthmatics were taking only inhaled, short-acting, beta (β~2~) agonists on an "as needed" basis for their asthma. At the time of the study, all asthmatics (smokers or non-smokers) were in a stable clinical condition, as demonstrated by the low daily variability (\<15%) of peak flow measurements during the two weeks prior to the study, and by the low variability in FEV~1~ performed during the study measurements. Peak flow measurements were performed only by the group of asthmatic patients.

Nine out of 31 COPD patients were under treatment with inhaled tiotropium and inhaled, short-acting, β~2~ agonists as needed. Ten were receiving inhaled, short-acting, β~2~ agonists or ipratropium as needed and none were receiving long-acting bronchodilators. Before each measurement, subjects were asked not to use long- or short-acting β~2~ agonists and/or ipratropium for at least 12 hours prior to the tests, and tiotropium for 48 hours prior to the tests.

Each subject attended the laboratory for three separate visits within one week. On the first visit, sputum induction was performed after a reversibility test. On the second visit, patients underwent a methacholine provocation challenge and skin prick testing, and on the third visit, an adenosine 5'monophosphate (AMP) provocation challenge was performed. No variability was observed in FEV~1~ on each visit during baseline spirometry performed before the provocation tests.

All subjects gave informed consent for their participation in the study, which was approved by the Hospital ethics committee.

Pulmonary function and bronchial hyperreactivity tests
------------------------------------------------------

Pulmonary function (FEV~1~ and FEV~1~/FVC) was measured with a dry wedge spirometer (Masterscreen, Jaeger, Hoechberg, Germany) according to standardized guidelines,[@b14-copd-5-287] by the same technician, using the same spirometer. Reversibility test was performed 20 minutes after inhalation of 200 μg salbutamol via a metered dose inhaler. ΔFEV~1~ was calculated as: post-bronchodilator FEV~1~ minus pre-bronchodilator FEV~1~/post-bronchodialator FEV~1~ × 100.

Methacholine chloride and AMP (both Sigma Chemical, St. Louis, MO) were dissolved in normal saline solution to produce doubling concentrations of 0.39--200 mg/mL for methacholine, and 0.04--320 mg/mL for adenosine, and immediately used for bronchial challenge (Masterscreen, Jaeger, Hoechberg, Germany).[@b16-copd-5-287],[@b17-copd-5-287] The first nebulization administered in each challenge was normal saline solution, and the post-saline solution FEV~1~ was used as the baseline for the calculation of subsequent percentage fall in FEV~1~. After challenge with saline solution, doubling concentrations of methacholine chloride were inhaled. Because of the effect of a deep inspiration on subsequent airway tone, only one measurement for FEV~1~ was performed, 60 to 90 seconds after inhalation of each concentration, unless the forced expiratory maneuvre was judged technically unsatisfactory.

The test was interrupted when a 20% decrease in FEV~1~ from the post-saline solution value was recorded, or when the highest concentration was reached. A log dose-response curve was constructed for each challenge, and the provocative dose of methacholine or AMP required to produce a 20% fall in FEV~1~ (PD~20~) was calculated by logarithmic interpolation.

Sputum induction and processing
-------------------------------

Sputum was induced by inhalation of hypertonic saline aerosol and processed as described previously.[@b18-copd-5-287] Briefly, 15 minutes after salbutamol inhalation (200 μg), normal saline (0.9%) and then hypertonic saline (3%, 4%, and 5%), nebulized by an ultrasonic nebulizer (ULTRA-NEB 2000, DeVilbiss Heathcare Inc, Somerset, USA), was inhaled for each concentration over a period of seven minutes. Subjects were encouraged to cough deeply after the seven minute intervals. All subjects produced an adequate aliquot of sputum which was processed within two hours after termination of the induction. Sputum samples were transferred to a petri dish and the volume and macroscopic characteristics of the whole sample recorded. Sputum plugs were separated from contaminating saliva using sterile forceps. The plugs were placed in a pre-weighed tube and the weight recorded. The sputum was then diluted three-fold with phosphate buffer solution containing freshly prepared dithiothreitol (Sigma Chemical Co, Poole, UK). Final concentration was 1 mmol/L. The sample was vortexed briefly and incubated at 37°C for 15 minutes with constant agitation. The suspension was filtered through monofilament filter cloth to remove mucus, centrifuged at 790 g-force for four minutes (4°C), and the pellet was re-suspended. Total cell counts were determined with a Neubauer haemocytometer (VWR International Ltd, Poole, UK) using tryptan blue exclusion to determine cell viability; dead cells and epithelial cells were excluded.

Cell smear preparations were made using a Cytospin 3 cytocentrifuge at 500 g-force for two minutes (Shandon Inc., Pittsburgh, PA, USA). Sputum cytospin slides were stained with May-Grünwald-Giemsa for differential cell counts. Counting of 400 non-squamous cells took place in a blinded fashion by one technician. Sputum samples containing \>20% of squamous cells and with cell viability \<70% were excluded from analysis as an indication of poor cytospin quality. The supernatant was stored at −80°C for subsequent assay for interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α) concentrations.

Measurement of IL-8 and TNF-α
-----------------------------

The concentrations of TNF-α and IL-8 were determined by enzyme-linked immunosorbent assay (ELISA), using kits purchased from R&D Systems (Minneapolis, Minnesota, USA). The assays were carried out according to the manufacturer's recommendations. The sensitivities of the assays used were 1.6 pg/ml and 3.5 pg/ml respectively.

Statistical analysis
--------------------

Data were expressed as mean (±SE) or median values. IL-8 and TNF-α were expressed as the median value and the inter-quartile range. All calculations of PD~20~ were performed with the base-2 logarithm (log~2~), as this reflects doubling concentrations and normalizes the distribution. Patients already responding to saline were assigned a PD~20~ value half of the lowest concentration applied. Patients not responding to the highest concentration of methacholine or AMP were assigned a value twice the highest concentration applied. Differences between subject groups were initially assessed using a Kruskal--Wallis test and if significant, a Mann--Whitney rank test was then performed. Correlations between inflammatory cells and cytokine levels in sputum, smoking characteristics, or lung function parameters were calculated using Spearman's rank correlation tests. Statistical analysis was not influenced by values at the lower limits of detection, since the non-parametric tests used were based on ranks of values. A *p* value of less than 0.05 was considered significant.

Results
=======

All smokers were matched for smoking pack-years. The clinical characteristics of the subjects participating in the study are shown in [Table 1](#t1-copd-5-287){ref-type="table"}. COPD smokers were older than "healthy" smokers, non-smokers, asthmatics, and smoking asthmatics (*P* \< 0.05).

Sputum cells -- cytokines
-------------------------

The median (inter-quartile range) of cell percentages and cytokines in sputum are shown in [Table 2](#t2-copd-5-287){ref-type="table"}. Smoking asthmatics had a significantly higher percentage of sputum neutrophils, and a significantly lower percentage of sputum eosinophils compared to non-smoking asthmatics (*P* \< 0.05). This increase was less than in COPD patients. COPD patients with reversibility had increased neutrophils and eosinophils (*P* \< 0.05) compared to asthma patients and compared to healthy control subjects (*P* \< 0.05). No difference was seen in neutrophil and eosinophil percentages between smoking asthmatics and COPD patients with reversibility. Eosinophils were decreased in COPD patients with or without reversibility, compared to non-smoking asthmatics (*P* \< 0.05).

A statistically significant difference in IL-8 sputum levels, but not in TNF-α, was observed in asthma groups. The cytokines IL-8 and TNF-α were significantly increased in COPD groups, whereas there was no difference in inflammatory cells and cytokines between the groups.

AHR
===

The mean PD~20~ methacholine and PD~20~AMP values, as well as the number of positive and negative provocation tests, are shown in [Table 3](#t3-copd-5-287){ref-type="table"}. There were no statistically significant differences between groups, although more positive AMP tests were found in smoking groups, namely smoking asthmatics and COPD groups.

Correlation among reversibility, inflammatory cells, and mediators
------------------------------------------------------------------

Reversibility was not correlated with inflammation, as expressed by sputum's inflammatory cells and cytokines IL-8 and TNF-α in asthma and COPD groups ([Table 4](#t4-copd-5-287){ref-type="table"}). However, ΔFEV~1~ was inversely correlated with sputum's neutrophils in smoking asthmatics ([Figure 1](#f1-copd-5-287){ref-type="fig"}).

Correlation among AHR, spirometry, inflammatory cells, and mediators
--------------------------------------------------------------------

In asthma groups (non-smoking and smoking), FEV~1~ (% of predicted) was correlated with PD~20~ methacholine (*r* = 0.637, *P* = 0.006 and *r* = 0.548, *P* = 0.028 respectively) and with PD~20~AMP (*r* = 0.527, *P* = 0.034 and *r* = 0.544, *P* = 0.021 respectively).

In non-smoking asthmatics, PD~20~ methacholine was correlated with FEV~1~/FVC (*r* = 0.641, *P* = 0.006) and Forced Expiratory Flow 25%--75% (FEF~25--75~) (*r* = 0.575, *P* = 0.05), whereas in smoking asthmatics, PD~20~AMP was correlated with FEV~1~/FVC (*r* = 0.565, *P* = 0.023) and FEF~25--75~ (*r* = 0.538, *P* = 0.031). Furthermore, PD~20~AMP was correlated with FEV~1~/FVC (*r* = 0.617, *P* = 0.019) and FEF~25--75~ (*r* = 0.627, *P* = 0.019) in COPD patients.

The response to AMP challenge was correlated with sputum's neutrophilia (*r* = 0.662, *P* = 0.004) only in COPD patients ([Figure 2](#f2-copd-5-287){ref-type="fig"}).

Discussion
==========

The main end-point of this study was to look for inflammatory parameters that might distinguish between asthma and COPD phenotypes in clinical practice. COPD patients with reversibility of airflow limitation did not differ significantly from smoking asthmatics. Interestingly, the percentage of sputum neutrophils was correlated with PD~20~AMP in COPD patients, but not in patients with asthma. This is a novel observation to the authors' knowledge. Finally, COPD patients, including the sub-group of COPD patients with reversibility, had significantly increased sputum IL-8 and TNF-α levels compared to smoking asthmatics.

The increased percentage of neutrophils in smoking asthmatics was not significantly different to that in COPD smokers. However, percentage of sputum neutrophils was inversely correlated with ΔFEV~1~ in smoking asthmatics, but not in COPD smokers or COPD patients with reversibility.

The inflammatory pattern in induced sputum of smoking patients with asthma and COPD has been previously studied.[@b19-copd-5-287]--[@b22-copd-5-287] Our findings are in keeping with those of Boulet et al who observed an increase in total cells and neutrophils in induced sputum of smoking asthmatics,[@b21-copd-5-287] and with those of Chalmers et al, who observed a significant decrease in sputum eosinophils in smoking asthmatics.[@b22-copd-5-287] The reasons for the reduction in eosinophils have not yet been elucidated. It is suggested that exogenous nitric oxide (NO) in cigarette smoke increases the apoptosis of activated eosinophils.[@b23-copd-5-287],[@b24-copd-5-287] Furthermore, it has been shown that nicotine within tobacco smoke exerts secondary immunomodulatory effects on eosinophil function, by inhibiting the release of pro-inflammatory cytokines from macrophages.[@b25-copd-5-287],[@b26-copd-5-287]

Interestingly, an inverse relationship between ΔFEV~1~ and the percentage of neutrophils in sputum of smoking asthmatics was shown, ie, the higher the sputum neutrophil count the lower the reversibility in currently smoking, steroid-naive, asthmatic patients. This finding is additive to the findings of previous studies, suggesting that neutrophilic inflammation contributes to irreversible airflow obstruction in asthma. Indeed, Shaw et al[@b27-copd-5-287] have previously shown that post-bronchodilator FEV~1~ is associated with sputum neutrophils. Increased sputum neutrophil count was associated with lower pre-bronchodilator FEV~1~, but to a lesser extent compared to the differential eosinophil count. Earlier studies have also shown a relationship between sputum neutrophils and FEV~1~. Woodruff et al[@b28-copd-5-287] demonstrated a relationship between airway neutrophilia and persistent airflow limitation in asthma. After correcting for confounding factors, their analysis demonstrated that increased sputum neutrophil percentage was independently associated with lower FEV~1~, but not with PC~20~ (the concentration of the agonist leading to a fall in FEV~1~ of 20%).

A study by Little et al[@b29-copd-5-287] also demonstrated that maximal FEV~1~ was inversely correlated with the duration of disease and sputum neutrophils. Since we did not find any correlation between neutrophil count in sputum and FEV~1~ in non-smoking asthmatics, our data suggest that smoking-induced neutrophilia might be an important mediator of airway narrowing in asthma. Indeed, neutrophils and their products could contribute to airway narrowing in asthma in several ways. Neutrophils might cause airway narrowing secondary to mucus hypersecretion, either indirectly, through the production of mediators such as neutrophilic elastase, or directly, through direct goblet cell/neutrophil interaction.[@b29-copd-5-287],[@b30-copd-5-287] In addition, neutrophil products might be important mediators of epithelial cell activation.[@b31-copd-5-287] Finally, neutrophil products can activate eosinophils.[@b32-copd-5-287] However, although neutrophils might exert specific effects on the airways, leading to chronic airway narrowing as a downstream effect of tissue injury, it is less clear if they release pro-inflammatory or pro-fibrotic cytokines.

The fact that we did not find any correlation between sputum neutrophil or sputum eosinophil percentages and ΔFEV~1~, in COPD patients or COPD patients with reversibility, is not peculiar. Papi et al[@b11-copd-5-287] also found increased sputum eosinophils in COPD with reversibility, but the reversibility of airflow limitation, expressed as percentage of predicted or absolute increase in FEV~1~ after inhaled salbutamol, did not correlate with any sputum inflammatory cell type. Furthermore, Gross et al[@b33-copd-5-287] showed that greater bronchodilator responses occurred in COPD patients with pre-bronchodilator FEV~1~ values \<55% of predicted, and were associated with cholinergic tone that was increased in proportion to the severity of airway obstruction. Therefore, it seems that the extent of bronchodilator response in COPD is not related to airway inflammation.

In this study, it was demonstrated that PD~20~ methacholine and PD~20~AMP levels are both associated with baseline FEV~1~ (% pred) in asthma groups, regardless of smoking habits. A positive correlation between the severity of bronchial hyperresponsiveness and FEV~1~ has been previously observed.[@b34-copd-5-287] This could be explained by the fact that a given stimulus will result in a larger bronchoconstrictor response in a subject with more severe airway obstruction than in a subject with less severe obstruction, resulting in a lower provocative concentration causing a 20% reduction in FEV~1~.[@b34-copd-5-287],[@b35-copd-5-287] Moreover, in non-smoking asthmatics, PD~20~ methacholine was positively correlated with FEV~1~/FVC and FEF~25--75~, whereas in smoking asthmatics and COPD patients, PD~20~AMP, but not PD~20~ methacholine, correlated with FEV~1~/FVC and FEF~25--75~, suggesting that PD~20~AMP provides a better reflection of disease severity in smoking related diseases. Methacholine acts directly on airway smooth muscle whereas AMP is an indirect stimulus that exerts its effect on inflammatory cells, subsequently leading to smooth muscle contraction and edema.[@b36-copd-5-287] Smoking can stimulate sensory nerve endings in the airway wall, which subsequently release tachykinins, which in turn can cause smooth muscle contraction via binding to specific cell receptors.[@b37-copd-5-287],[@b38-copd-5-287] This is a possible pathway for the effect of AMP in smoking patients. Furthermore, tachykinins may enhance hyperresponsiveness via induction of airway wall edema and mucus hypersecretion, and possibly via induction of smooth muscle hypertrophy resulting from chronic stimulation. Moreover, they can induce recruitment of inflammatory cells into the airways.[@b36-copd-5-287] Therefore, airway hyperresponsiveness to AMP provides additional information with regard to airway inflammation and disease severity in smoking asthmatics and COPD patients.

Surprisingly, in asthmatic patients, no correlation was found between AHR and inflammatory cells and mediators. AMP mainly acts via the release of mast cell mediators. The majority of studies on AMP responsiveness have been conducted in allergic patients.[@b39-copd-5-287],[@b40-copd-5-287]

In order to describe the relationship between AHR and airway inflammation, excluding the potential confounding benefit of steroids, the subjects included were steroid-naive patients for at least three months. The absence of inhaled steroids, the clinical status (stable disease without symptoms for at least three months), and the presence of both atopic and non-atopic patients, might explain why we did not observe any association between sputum cells and AHR with both methacholine and AMP. In support of our findings, data from murine models show that AHR appears to be dissociated from eosinophilic inflammation.[@b41-copd-5-287],[@b42-copd-5-287]

In COPD patients, a positive correlation between sputum neutrophil percentage and AHR was observed, suggesting a role of neutrophils in airway hyperresponsiveness. Willemse et al[@b43-copd-5-287] studied the effect of smoking cessation on sputum inflammation and methacholine and AMP stimuli in smoker COPD patients. They showed that smoking cessation improved both direct and indirect airway hyperresponsiveness and that the number of neutrophils increased after six months smoking cessation and increased even more after 12 months smoking cessation. Our results might provide an explanation for these findings. Moreover, Cui et al[@b44-copd-5-287] transferred Type 1 helper T (T~h~1) cells into IL-8 RRO mice in order to evaluate whether IL-8 plays a role in T~h~1-induced AHR. They found no reduction in AHR. Their study in mice is in line with our study in COPD patients, in which AHR correlates with sputum neutrophils, but not with IL-8 levels in sputum.

IL-8 sputum levels were statistically significantly higher in smoking asthmatics compared to non-smoking asthmatics, and although TNF-α levels were also higher in smoking asthmatics, the difference was not significant compared to non-smoking asthmatics. IL-8 is a pro-inflammatory mediator and a neutrophil chemoattractant.[@b44-copd-5-287] However, in stable asthma and COPD patients, it is not clear whether IL-8 plays a role as a chemoattractant for neutrophils, or as a proinflammatory mediator that is released from neutrophils. There was no correlation between IL-8 and TNF-α and ΔFEV~1~ and AHR. Since we did not find IL-8 to be correlated with ΔFEV~1~, it might be suggested that IL-8 acts as an indicator of the severity of neutrophilic inflammation, rather than as an indicator of pulmonary function. Finally, IL-8 and TNF-α were significantly increased in COPD patients with reversibility, compared to smoking and non-smoking asthmatics, whereas no difference was found in inflammatory cells and cytokines between the COPD groups.

In conclusion, it is evident, that the effect of smoking on airway inflammation is important and may influence the physiological characteristics of the airways differently in asthma and in COPD. Moreover, the different sputum inflammatory profile in smoking asthmatics and COPD patients, including COPD patients with reversibility, provides a role for sputum induction in clinical practice. However, more studies are needed in order for cut off values that differentiate asthma from COPD to be determined. Finally, the combination of sputum induction, reversibility, and AHR tests might be useful in diagnosing and monitoring chronic inflammatory airway diseases, and better managing their treatment.

**Author contributions**

ED and NR carried out the sampling and measurement of mediators, participated in the design and statistical analysis, and drafted the manuscript. CG analyzed the ELISAs. CGr conceived of the study and participated in its design and coordination. CR participated in coordination. All authors read and approved the final manuscript.

**Disclosure**

The authors declare that they have no competing interests.

![Spearman's rank correlation: ΔFEV~1~ and sputum neutrophil count in smoking asthmatics (n = 24).](copd-5-287f1){#f1-copd-5-287}

![Spearman's rank correlation: PD~20AMP~ and sputum neutrophil percentage in COPD patients with reversibility (n = 10) and without reversibility (n = 21).](copd-5-287f2){#f2-copd-5-287}

###### 

Subject characteristics

                         **Healthy (n = 17)**   **Healthy smokers (n = 16)**   **Asthmatics (n = 22)**                                                                          **Smoking asthmatics (n = 24)**                                                                                                              **COPD (n = 21)**                                                                                                                                                                      **COPD Reversibility (n = 10)**
  ---------------------- ---------------------- ------------------------------ ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age (yrs)              41.5 ± 3.5             40.9 ± 1.9                     45.2 ± 2.2                                                                                       49.4 ± 1.8                                                                                                                                   58.4 ± 2.0[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                                                                       55.2 ± 5.0[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}
  Smoking (pack-years)   0                      44.6 ± 4.3                     0                                                                                                39.4 ± 4.6                                                                                                                                   50.7 ± 4.9                                                                                                                                                                             52.1 ± 5.4
  FEV~1~ (L)             3.3 ± 0.2              3.4 ± 0.2                      3.2 ± 0.2                                                                                        2.7 ± 0.1[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                              2.1 ± 0.2[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                                                                        2.3 ± 0.3[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}
  FEV~1~ (% pred)        104.7 ± 3.1            102.7 ± 2.3                    98.5 ± 3.5                                                                                       86.1 ± 3.5[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                             67.6 ± 3.3[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                                                                       66.1 ± 5.3[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}
  ΔFEV~1~                1.5 ± 0.4              1.0 ± 0.2                      14 ± 0.6[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}   9.5 ± 1.8[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                              2.8 ± 1.0[†](#tfn4-copd-5-287){ref-type="table-fn"}[‡](#tfn5-copd-5-287){ref-type="table-fn"}[\*\*](#tfn6-copd-5-287){ref-type="table-fn"}                                             7.5 ± 1.6[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}[†](#tfn4-copd-5-287){ref-type="table-fn"}
  FVC (L)                4.2 ± 0.2              4.3 ± 0.2                      4.0 ± 1.0                                                                                        3.9 ± 1.2                                                                                                                                    3.7 ± 2.1[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                                                                        3.8 ± 0.3[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}
  FVC (% pred)           106.8 ± 2.4            108.3 ± 5.7                    104.3 ± 3.3                                                                                      97.8 ± 3.1                                                                                                                                   84.1 ± 4.3[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                                                                       89.9 ± 4.0[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}
  FEV~1~/FVC             83.0 ± 1.5             80.6 ± 1.2                     78.6 ± 1.5                                                                                       72.3 ± 2.1[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                             63.9 ± 1.9[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}[†](#tfn4-copd-5-287){ref-type="table-fn"}[‡](#tfn5-copd-5-287){ref-type="table-fn"}   59.98 ± 2.9[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}[†](#tfn4-copd-5-287){ref-type="table-fn"}[‡](#tfn5-copd-5-287){ref-type="table-fn"}
  FEF~25--75~ (L)        3.6 ± 0.4              3.3 ± 0.3                      3.2 ± 0.3                                                                                        2.1 ± 0.2[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}[†](#tfn4-copd-5-287){ref-type="table-fn"}    1.1 ± 0.1[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}                                                                                        1.4 ± 0.3[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}
  FEF~25--75~ (% pred)   92.0 ± 7.9             82.5 ± 4.9                     77.1 ± 5.7                                                                                       55.8 ± 5.2[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}[†](#tfn4-copd-5-287){ref-type="table-fn"}   33.2 ± 2.4[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}[†](#tfn4-copd-5-287){ref-type="table-fn"}[‡](#tfn5-copd-5-287){ref-type="table-fn"}   30.5 ± 3.2[\*](#tfn2-copd-5-287){ref-type="table-fn"}[\#](#tfn3-copd-5-287){ref-type="table-fn"}[†](#tfn4-copd-5-287){ref-type="table-fn"}[‡](#tfn5-copd-5-287){ref-type="table-fn"}
  RV (% pred)            99.1 ± 4.8             90.9 ± 3.5                     102.0 ± 10.1                                                                                     106.0 ± 5.7                                                                                                                                  94.2 ± 8.7                                                                                                                                                                             96.5 ± 5.3
  TLC (% pred)           94.4 ± 2.6             96.5 ± 2.4                     91.5 ± 3.0                                                                                       92.7 ± 2.6                                                                                                                                   84.2 ± 5.2                                                                                                                                                                             90.6 ± 4.8
  FRC (% pred)           94.2 ± 4.9             96.2 ± 5.3                     84.6 ± 6.0                                                                                       91.4 ± 4.4                                                                                                                                   99.6 ± 4.3                                                                                                                                                                             103.2 ± 5.7
  DLCO (% pred)          98.0 ± 5.0             82.9 ± 3.7                     103.5 ± 4.5                                                                                      95.1 ± 3.0                                                                                                                                   77.9 ± 5.4[\*](#tfn2-copd-5-287){ref-type="table-fn"}[†](#tfn4-copd-5-287){ref-type="table-fn"}                                                                                        78.5 ± 5.9[\*](#tfn2-copd-5-287){ref-type="table-fn"}[†](#tfn4-copd-5-287){ref-type="table-fn"}

**Notes:** Values are expressed as mean ± SE.

denotes a significant difference vs healthy subjects;

vs healthy smokers;

vs asthmatics;

vs smoking asthmatics; and

vs COPD with reversibility (*P* \< 0.05).

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; FEF~25--75~, forced expiratory flow 25--75; RV, residual volume; TLC, total lung capacity; FRC, forced residual capacity; DLCO, diffusing lung capacity for carbon monoxide.

###### 

Patterns of inflammatory markers within clinical diagnosis groups

                  **Healthy (n = 7)**   **Healthy smokers (n = 16)**   **Asthmatics (n = 22)**                                                                                   **Smoking asthmatics (n = 24)**                                                                                                                        **COPD (n = 21)**                                                                                                                                                                                  **COPD Reversibility (n = 10)**
  --------------- --------------------- ------------------------------ --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Neutrophils %   41.3 (12.0--79.5)     47.4 (19.1--1.3)               22.5 (0.5--66.3)                                                                                          50.1[†](#tfn11-copd-5-287){ref-type="table-fn"} (3.6--90.9)                                                                                            67.9[\*](#tfn9-copd-5-287){ref-type="table-fn"}[\#](#tfn10-copd-5-287){ref-type="table-fn"}[†](#tfn11-copd-5-287){ref-type="table-fn"} (16.8--92.5)                                                69.2[\*](#tfn9-copd-5-287){ref-type="table-fn"}[\#](#tfn10-copd-5-287){ref-type="table-fn"}[†](#tfn11-copd-5-287){ref-type="table-fn"} (17.3--86.3)
  Eosinophils %   0.90 (0.3--6.5)       0.35 (0.1--2.1)                3.9[\*](#tfn9-copd-5-287){ref-type="table-fn"}[\#](#tfn10-copd-5-287){ref-type="table-fn"} (1.5--18.0)    1.5[\#](#tfn10-copd-5-287){ref-type="table-fn"}[†](#tfn11-copd-5-287){ref-type="table-fn"} (0.3--20.8)                                                 1.00[†](#tfn11-copd-5-287){ref-type="table-fn"} (0.2--3.4)                                                                                                                                         1.9[\#](#tfn10-copd-5-287){ref-type="table-fn"}[†](#tfn11-copd-5-287){ref-type="table-fn"} (0.7--4.5)
  IL-8 (pg/ml)    750 (280--46176)      1130 (90--30570)               6410[\*](#tfn9-copd-5-287){ref-type="table-fn"}[\#](#tfn10-copd-5-287){ref-type="table-fn"} (727--9520)   10159[\*](#tfn9-copd-5-287){ref-type="table-fn"}[\#](#tfn10-copd-5-287){ref-type="table-fn"}[†](#tfn11-copd-5-287){ref-type="table-fn"} (194--61776)   20370[\*](#tfn9-copd-5-287){ref-type="table-fn"}[\#](#tfn10-copd-5-287){ref-type="table-fn"}[†](#tfn11-copd-5-287){ref-type="table-fn"}[‡](#tfn12-copd-5-287){ref-type="table-fn"} (5090--64100)   19130[\*](#tfn9-copd-5-287){ref-type="table-fn"}[\#](#tfn10-copd-5-287){ref-type="table-fn"}[†](#tfn11-copd-5-287){ref-type="table-fn"}[‡](#tfn12-copd-5-287){ref-type="table-fn"} (7480--39410)
  TNF-α (pg/ml)   13.7 (1.5--34.8)      19.7 (6.8--76.4)               6.7[\*](#tfn9-copd-5-287){ref-type="table-fn"}[\#](#tfn10-copd-5-287){ref-type="table-fn"} (1.5--37.7)    7.7[\#](#tfn10-copd-5-287){ref-type="table-fn"} (22.5--139.2)                                                                                          50.6[\*](#tfn9-copd-5-287){ref-type="table-fn"}[\#](#tfn10-copd-5-287){ref-type="table-fn"}[†](#tfn11-copd-5-287){ref-type="table-fn"}[‡](#tfn12-copd-5-287){ref-type="table-fn"} (2.6--90.3)      47.9[\#](#tfn10-copd-5-287){ref-type="table-fn"}[†](#tfn11-copd-5-287){ref-type="table-fn"}[‡](#tfn12-copd-5-287){ref-type="table-fn"} (22.5--139.2)

**Notes:** Values are expressed as median values (inter-quartile range).

denotes a significant difference vs healthy subjects;

vs healthy smokers;

vs asthmatics; and

vs smoking asthmatics (*P* \< 0.05).

**Abbreviations:** IL-8, interleukin-8; TNF-α, tumor necrosis factor-alpha.

###### 

PD~20meth~ and PD~20AMP~ in clinical diagnosis groups

                          **Asthmatics (n = 22)**   **Smoking asthmatics (n = 24)**   **COPD (n = 21)**      **COPD Reversibility (n = 10)**
  ----------------------- ------------------------- --------------------------------- ---------------------- ---------------------------------
  PD~20meth~ (mcg)(+/−)   533.1 ± 345.5 (13/4)      513.5 ± 322.7 (11/6)              692.0 ± 340.7 (4/10)   495.0 ± 153.0 (6/4)
  PD~20AMP~ (mcg)(+/−)    3.8 ± 1.67 (12/6)         3.5 ± 1.67 (13/4)                 3.2 ± 0.5 (7/7)        2.6 ± 0.5 (7/3)

**Notes:** Values are expressed as mean ± SE. Figures in brackets refer to the number of positive and negative provocation tests.

**Abbreviations:** PD~20meth~, provocative dose of methacholine required to produce a 20% fall in FEV~1~; PD~20AMP~, provocative dose of AMP required to produce a 20% fall in FEV~1~.

###### 

Correlations between reversibility, inflammatory cells, and mediators

                **Asthmatics (n = 22)**   **Smoking asthmatics (n = 24)**   **COPD (n = 31)**                             
  ------------- ------------------------- --------------------------------- ------------------- --------------- --------- ---------------
  ΔFEV~1~       ***r***                   ***P* value**                     ***r***             ***P* value**   ***r***   ***P* value**
  Eosinophils   0.47                      0.06                              0.17                0.49            −0.11     0.67
  Neutrophils   0.13                      0.65                              −0.56               0.04            0.15      0.49
  IL-8          0.33                      0.42                              0.48                0.85            −0.18     0.43
  TNF-α         0.56                      0.92                              0.22                0.32            0.70      0.76

**Abbreviations:** ΔFEV~1~, change in forced expiratory volume in one second; IL-8, interleukin-8; TNF-α, tumor necrosis factor-alpha.

[^1]: These authors contributed equally to this work
